GlassScriptPhysician profile
Rebekah Pennington
NPI 1487137931
$1,459.62
in general payments reported to CMS, 2019-2025
22 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $221 · 2022: $148 · 2023: $124 · 2024: $621 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,010.78 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $246.42 | 2021-2025 | Kisqali, Piqray |
| Lilly USA, LLC | $175.84 | 2022-2024 | Retevmo, Jaypirca, Verzenio |
| Pfizer INC. | $125.56 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $103.88 | 2021 | |
| Genentech USA, INC. | $82.80 | 2024 | Tecentriq, Alecensa, Rozlytrek |
| Sobi, INC | $79.99 | 2025 | |
| Celgene Corporation | $77.75 | 2023-2024 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $76.02 | 2021-2025 | Keytruda, Lynparza |
| Astellas Pharma US INC | $64.43 | 2024-2025 | Padcev, Xospata |
| Genzyme Corporation | $63.35 | 2024-2025 | |
| Array Biopharma INC | $59.74 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Janssen Biotech, INC. | $51.35 | 2023-2024 | Imbruvica, Darzalex, Tecvayli |
| Glaxosmithkline, LLC. | $43.55 | 2024-2025 | Ojjaara |
| Incyte Corporation | $28.80 | 2024 | Jakafi |
| Aveo Pharmaceuticals, INC. | $28.65 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $26.45 | 2023 | Calquence |
| Pharmacosmos Therapeutics INC. | $23.57 | 2024 | Cosela |
| Gilead Sciences, INC. | $23.41 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.73 | 2024 | |
| Rigel Pharmaceuticals, INC. | $21.29 | 2024 | Tavalisse, Rezlidhia |
| Abbvie INC. | $21.24 | 2021 | |
| Seagen INC. | $12.80 | 2023 | Padcev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebekah Pennington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.